Angiotensin-(1-7), a protective peptide, reversed TNF-α-induced suppression of mitochondrial transcription factors in heart cells by restoring the PGC-1α-YY1 transcriptional complex — revealing a new mechanism for cardiac protection.
PGC-1α-YY1 molecular switchTNF-α disrupts this transcriptional complex to silence mitochondrial genes in heart cells, and Angiotensin-(1-7) restores it — revealing a targetable mechanism for cardiac mitochondrial protection
What the researchers found
Mitochondrial transcription factors (Tfam, Tfb1m, Tfb2m) were significantly reduced in the left ventricle of spontaneously hypertensive rats (SHR) compared to normotensive controls (WKY). TNF-α treatment of H9c2 cardiomyoblasts similarly suppressed these mitochondrial transcription factors.
Angiotensin-(1-7) reversed the TNF-α-mediated repression of all three mitochondrial transcription factors in vitro. The mechanism involved the PGC-1α-YY1 transcriptional complex: TNF-α prevented formation of this complex, allowing YY1 alone to repress mitochondrial transcription factor genes. Ang-(1-7) restored PGC-1α-YY1 complex formation, reactivating transcription. This establishes the PGC-1α-YY1 complex as a molecular switch and Ang-(1-7) as a regulator of cardiac mitochondrial biogenesis under inflammatory conditions.
Why it matters
Mitochondrial dysfunction is a central feature of heart failure caused by chronic hypertension, but the molecular mechanisms connecting inflammation to mitochondrial decline have been poorly understood. This study identifies a specific pathway — TNF-α disrupting PGC-1α-YY1 to silence mitochondrial genes — and shows that the peptide Ang-(1-7) can reverse it. This has direct therapeutic implications because Ang-(1-7) and its analogs are already being explored as cardiovascular drugs.
How the study worked
The study combined in vivo and in vitro approaches. Left ventricular tissue from spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY) was analyzed for mitochondrial transcription factor expression. H9c2 cardiomyoblast cells were treated with TNF-α alone or TNF-α plus Angiotensin-(1-7) to assess effects on mtTF expression. Protein-protein interaction studies characterized the PGC-1α-YY1 complex formation under different treatment conditions. Gene expression and transcriptional activity were measured.
What this study cannot tell us
The in vivo data comes from spontaneously hypertensive rats (a genetic model), which may not fully represent human hypertensive heart disease. The in vitro experiments used H9c2 cardiomyoblasts (a cell line), which differ from primary cardiomyocytes. The study demonstrates the mechanism in vitro but does not show that Ang-(1-7) restores mitochondrial function in hypertensive hearts in vivo. Specific concentrations and treatment durations were not detailed in the abstract. The translational potential to human heart failure requires further validation.
How to read the evidence
This is a mechanistic study combining in vivo observation (hypertensive vs. normotensive rat hearts) with in vitro molecular analysis (cell culture with TNF-α and Ang-(1-7)). The mechanistic detail is strong, identifying a specific transcriptional complex. However, the therapeutic demonstration is limited to cell culture, and in vivo Ang-(1-7) treatment was not performed.
When this study was published
Published in 2026, this is extremely current research that adds to the growing understanding of Ang-(1-7)'s cardioprotective mechanisms. The mitochondrial protection angle is a relatively new direction for this well-studied peptide.
The bigger picture
Angiotensin-(1-7) is part of the 'protective arm' of the renin-angiotensin system — it counteracts the harmful effects of Angiotensin II that drives hypertension. While Ang-(1-7) has been studied for blood pressure regulation and anti-inflammatory effects, this study adds a new dimension: direct protection of cardiac mitochondrial biogenesis. As heart failure research increasingly focuses on mitochondrial health, Ang-(1-7) and its analogs could emerge as multi-target cardiovascular therapeutics that address both inflammation and energy metabolism.
Questions still open
- Does in vivo administration of Ang-(1-7) to hypertensive rats restore mitochondrial transcription factors and improve cardiac function?
- Could Ang-(1-7) analogs or Mas receptor agonists be developed specifically to target cardiac mitochondrial dysfunction in heart failure?
- Is the PGC-1α-YY1 disruption mechanism also operative in other inflammatory conditions affecting the heart, like myocarditis?
Common questions
What is Angiotensin-(1-7) and how does it protect the heart?
Why are mitochondria important for heart health?
Read the original research
TNF-α-mediated down-regulation of mitochondrial transcription factors: Rescue by Angiotensin-(1-7) peptide.
Mitochondrion, 88, 102130
Citation
Natarajan, Bhargavi; Vijayakumar, Anupama; Iyer, Dhanya R; Venkatraman, Janani; Arige, Vikas; Khan, Abrar A; Barthwal, Manoj K; Kontos, Christopher; Mahapatra, Nitish R. (2026). TNF-α-mediated down-regulation of mitochondrial transcription factors: Rescue by Angiotensin-(1-7) peptide.. Mitochondrion, 88, 102130. https://doi.org/10.1016/j.mito.2026.102130